(PCVX) Vaxcyte - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 6.811m USD | Total Return: 39.5% in 12m
Industry Rotation: -8.2
Avg Turnover: 73.8M
Qual. Beats: -3
Qual. Beats: 0
Warnings
Altman Z'' -8.67 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Vaxcyte, Inc. is a clinical-stage biotechnology firm specializing in the development of conjugate and protein vaccines targeting bacterial infections. Its primary focus is the pneumococcal conjugate vaccine (PCV) market, led by candidates VAX-24 and VAX-31, which aim to prevent invasive pneumococcal disease across pediatric and adult populations. The company utilizes a proprietary cell-free protein synthesis platform designed to overcome the carrier suppression limitations often found in traditional vaccine manufacturing.
The vaccine sector is characterized by high barriers to entry and long development cycles, often requiring extensive clinical trials to meet stringent safety and efficacy standards for public health use. Vaxcyte’s pipeline extends beyond respiratory pathogens to include candidates for Group A Streptococcus, periodontitis, and Shigella. Examining the historical performance of similar clinical-stage biotechs on ValueRay can provide useful context for evaluating its current trajectory.
Headquartered in San Carlos, California, the company transitioned from its original name, SutroVax, in 2020. Its business model relies on advancing its investigational candidates through the regulatory pipeline to address unmet needs in the global infectious disease landscape.
- Clinical trial data for VAX-31 and VAX-24 determines competitive positioning against Pfizer
- Regulatory approval timelines for infant pneumococcal vaccines dictate long-term market entry
- Manufacturing scalability and production costs impact future gross margins for conjugate vaccines
- Market share competition with established incumbents Pfizer and Merck drives valuation
- Capital expenditure requirements for late-stage clinical trials influence future equity financing needs
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.23 > 0.02 and ΔFCF/TA -5.29 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.23 > 3% & CFO -769.9m > Net Income -946.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (139.5m) vs 12m ago 2.81% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.47 (Total Current Assets 1.81b - Total Current Liabilities 242.1m) / Total Assets 3.35b |
| B: -0.74 (Retained Earnings -2.48b / Total Assets 3.35b) |
| C: -0.29 (EBIT TTM -971.8m / Avg Total Assets 3.36b) |
| D: -7.05 (Book Value of Equity -2.48b / Total Liabilities 352.3m) |
| Altman-Z'' = -8.67 = D |
Over the past week, the price has changed by -11.47%, over one month by -21.73%, over three months by -21.36% and over the past year by +39.51%.
- StrongBuy: 9
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 109 | 130% |
Revenue TTM = 0.0 USD
EBIT TTM = -971.8m USD
EBITDA TTM = -945.9m USD
Long Term Debt = 110.2m USD (estimated: total debt 116.3m - short term 6.08m)
Short Term Debt = 6.08m USD (from shortTermDebt, last quarter)
Debt = 116.3m USD (from shortLongTermDebtTotal, last quarter) (leases 116.3m already included)
Net Debt = -1.62b USD (calculated: Debt 116.3m - CCE 1.74b)
Enterprise Value = 5.19b USD (6.81b + Debt 116.3m - CCE 1.74b)
Interest Coverage Ratio = unknown (Ebit TTM -971.8m / Interest Expense TTM 0.0)
EV/FCF = -6.73x (Enterprise Value 5.19b / FCF TTM -771.7m)
FCF Yield = -14.87% (FCF TTM -771.7m / Enterprise Value 5.19b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 5.85m) / Revenue TTM)
Tobins Q-Ratio = 1.55 (Enterprise Value 5.19b / Total Assets 3.35b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 116.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -767.7m (EBIT -971.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.49 (Total Current Assets 1.81b / Total Current Liabilities 242.1m)
Debt / Equity = 0.04 (Debt 116.3m / totalStockholderEquity, last quarter 3.00b)
Debt / EBITDA = 1.71 (negative EBITDA) (Net Debt -1.62b / EBITDA -945.9m)
Debt / FCF = 2.10 (negative FCF - burning cash) (Net Debt -1.62b / FCF TTM -771.7m)
Total Stockholder Equity = 2.91b (last 4 quarters mean from totalStockholderEquity)
RoA = -28.14% (Net Income -946.5m / Total Assets 3.35b)
RoE = -17.57% (Net Income TTM -946.5m / Total Stockholder Equity 5.39b)
RoCE = -17.68% (EBIT -971.8m / Capital Employed (Equity 5.39b + L.T.Debt 110.2m))
RoIC = -55.83% (negative operating profit) (NOPAT -767.7m / Invested Capital 1.38b)
WACC = 9.19% (E(6.81b)/V(6.93b) * Re(9.35%) + D(116.3m)/V(6.93b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 13.74%
[DCF] Fair Price = unknown (Cash Flow -771.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.16 | # QB: -3
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-2.10 | Chg30d=-13.48% | Revisions=-50% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-2.16 | Chg30d=-9.86% | Revisions=-50% | Analysts=7
EPS current Year (2026-12-31): EPS=-8.48 | Chg30d=-14.79% | Revisions=-56% | GrowthEPS=-50.7% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-7.42 | Chg30d=-1.83% | Revisions=-33% | GrowthEPS=+12.5% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -56%